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Abstract
Introduction Intensive insulin therapy (IIT) with tight glycemic
control may reduce mortality and morbidity in critically ill patients
and has been widely adopted in practice throughout the world.
However, there is only one randomized controlled trial showing
unequivocal benefit to this approach and that study population
was dominated by post-cardiac surgery patients. We aimed to
determine the association between IIT and mortality in a mixed
population of critically ill patients.
Methods We conducted a cohort study comparing three
consecutive time periods before and after IIT protocol
implementation in a Level 1 trauma center: period I (no
protocol); period II, target glucose 80 to 130 mg/dL; and period
III, target glucose 80 to 110 mg/dL. Subjects were 10,456
patients admitted to intensive care units (ICUs) between 1
March 2001 and 28 February 2005. The main study endpoints
were ICU and hospital mortality, Sequential Organ Failure
Assessment score, and occurrence of hypoglycemia.
Multivariable regression analysis was used to evaluate mortality
and organ dysfunction during periods II and III relative to period I.
Results Insulin administration increased over time (9% period I,
25% period II, and 42% period III). Nonetheless, patients in
period III had a tendency toward higher adjusted hospital
mortality (odds ratio [OR] 1.15, 95% confidence interval [CI]
0.98, 1.35) than patients in period I. Excess hospital mortality in
period III was present primarily in patients with an ICU length of
stay of 3 days or less (OR 1.47, 95% CI 1.11, 1.93 There was
an approximately fourfold increase in the incidence of
hypoglycemia from periods I to III.
Conclusion A policy of IIT in a group of ICUs from a single
institution was not associated with a decrease in hospital
mortality. These results, combined with the findings from several
recent randomized trials, suggest that further study is needed
prior to widespread implementation of IIT in critically ill patients.
Introduction
Stress-induced hyperglycemia occurs frequently in critically ill
patients and has been associated with increased morbidity
and mortality in both diabetic and non-diabetic patients and in
patients with traumatic injury [1-3], stroke [4-7], anoxic brain
injury [8], acute myocardial infarction [9], post-cardiac surgery
[10], and other causes of critical illness [11-13]. If causal, the
mechanisms by which hyperglycemia affects outcomes could
be related to suppressive effects on immune function and an
associated increased risk of infection [14-16], endothelial
damage [17], hepatocyte mitochondrial damage [18], and
potentiation of tissue ischemia due to acidosis or inflammation
[19,20].
Two observational [21,22] and two randomized [23,24] trials
of surgical and medical critically ill patients have observed a
higher incidence of favorable outcomes in critically ill patients
treated with intensive insulin therapy (IIT) to achieve a blood
glucose level of 80 to 110 mg/dL. However, other recently
published studies suggest that there may be no benefit or
APS = Acute Physiologic Score; CI = confidence interval; ICU = intensive care unit; IIT = intensive insulin therapy; LOS = length of stay; OR = odds 
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even harm conferred by this approach in patients during car-
diac surgery or recovering from cardiac arrest [25,26]. In addi-
tion, two recent randomized trials of IIT in critically ill patients
were stopped early due to lack of benefit and hypoglycemia
associated with IIT [27].
Although there is still debate whether the evidence is ade-
quate to support a clear recommendation, the Institute for
Healthcare Improvement [28] is recommending a care 'bun-
dle' for severe sepsis which includes intensive glycemic con-
trol. Likewise, the Volunteer Hospital Association [29] uses
glucose control as a quality indicator. As a result of these rec-
ommendations (which were made prior to the availability of the
results from the most recent studies), tight glycemic control
has increasingly become the standard of care for critically ill
patients at our institution.
The objective of the present study was to investigate the effect
of implementing a policy of tight glycemic control in a broader
population of critically ill patients than previously studied,
including a mix of trauma, surgical, neurosurgical, and medical
intensive care unit (ICU) patients. To this end, we examined
the outcomes of all patients admitted to the ICUs at Harbor-
view Medical Center, a Level I trauma center and county hos-
pital in Seattle, WA, before and after the introduction of
intensive insulin protocols.
Materials and methods
Source population
Harborview Medical Center is a 374-bed municipal medical
center affiliated with the University of Washington, Seattle,
WA, and the only Level 1 trauma center in a five-state area
(Washington, Wyoming, Alaska, Montana, and Idaho). There
are seven ICUs located at Harborview Medical Center, serving
a variety of patients with medical and surgical illness. The
majority of patients are covered by ICU services with intensive
staffing models, and all critical care protocols are implemented
throughout all ICUs simultaneously. Nursing staffing ratios
remained constant throughout the study period. For the pur-
pose of this study, a cohort of all patients admitted to these
ICUs over the course of a 4-year period between 1 March
2001 and 28 February 2005 was selected. All data were avail-
able from the hospital database originating from computerized
medical and billing records and from a prospectively collected
registry of trauma-related admissions [30]. The study was
approved by the University of Washington Institutional Review
Board, which waived the need for informed consent.
Study design
The cohort was divided into three periods corresponding to
changing glycemic control goals and insulin therapy protocols:
period I, 1 March 2001 to 28 February 2002; during this
period, there was no specific glycemic control protocol, and
hyperglycemia was treated by a mix of subcutaneous and intra-
venous insulin, with a general target blood glucose of 120 to
180 mg/dL; period II, 1 March 2002 to 30 June 2003 (target
blood glucose of 80 to 130 mg/dL); and period III, 1 July 2003
to 28 February 2005 (80 to 110 mg/dL). Study period was
considered as a surrogate of IIT and was used as the main pre-
dictor of interest. The intensive insulin protocols consisted of
explicit target glucose ranges and of dosing orders for intrave-
nous insulin by continuous infusion combined with intravenous
boluses if necessary (Appendix 1). In addition, educational
efforts were directed at physicians and nursing staff to empha-
size the potential benefits of tight glycemic control and to alert
practitioners to the protocols. There were no major changes in
glycemic management on the acute care wards during the
study periods. Three other critical care protocols designed to
improve clinical outcomes were implemented at the study hos-
pital in 2001–2003: (a) a procedure for invasive diagnosis of
ventilator-associated pneumonia (fall of 2001), (b) a lung pro-
tective ventilation protocol (spring of 2002), and (c) a protocol
for liberation from mechanical ventilation (spring of 2003).
There were no changes in the indications for admission to the
ICU during the study period.
For each patient, only the first ICU stay per hospitalization and
the first hospital stay were included in this analysis. Patients
were excluded if their ICU stay was shorter than 24 hours or if
the ICU stay was not completed before the end of the study
period during which they were admitted. Patients younger than
16 years of age were also excluded.
Blood glucose levels obtained closest in time to 6 a.m. were
collected from the central laboratory analyzer. This convention
was chosen based on reporting of glycemic control in the two
large randomized trials of IIT in critically ill patients and to pro-
vide consistency in reporting given the potential inaccuracy of
capillary point-of-care glucose measurements in critically ill
patients [23,24,31]. For frequency of hypoglycemia, data were
included from both central laboratory measurements and
point-of-care glucose testing in order to capture all hypoglyc-
emic events.
Patients were classified by the admitting ICU service (surgical,
medical, coronary, neurosurgical, or burn) and by the type of
admission (surgical versus medical). The latter was deter-
mined by which service the majority of time in the ICU was
spent after admission. Surgical admissions include those
patients who spent the majority of their ICU time on the surgi-
cal, neurosurgical, or burn ICU services. In addition, the pro-
portion of patients admitted after trauma was determined.
Statistical analysis
Primary outcome measures defined a priori included ICU and
hospital mortality. Secondary safety outcome measures
included occurrence of moderate (glucose of less than 65 mg/
dL) and severe (glucose of less than 40 mg/dL) hypoglycemia
at any time during the ICU stay. Additional a priori-specified
secondary outcomes included evidence of organ dysfunctionAvailable online http://ccforum.com/content/12/1/R29
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as measured by Sequential Organ Failure Assessment
(SOFA) scores.
Confounders were selected on the basis of a priori knowledge
to account for severity of disease and other risk factors. Sever-
ity of illness was measured by the Simplified Acute Physiology
Score (SAPS) II and the Acute Physiologic Score (APS) of the
APACHE (Acute Physiology and Chronic Health Evaluation) III
score in the first 24 hours of ICU admission in all patients;
these scores were calculated from information available in the
electronic medical record. The Injury Severity Score was
obtained in all patients admitted after traumatic injury from the
Harborview Trauma Registry. Other potential confounders that
were adjusted for included age, race, gender, comorbidities as
defined by SAPS II, mechanical ventilation at ICU admission,
and history of diabetes.
We evaluated the distribution of baseline characteristics and
their association with the mortality among patients admitted to
the ICU during each respective insulin protocol implementa-
tion period (study period), using one-way analysis of variance
or frequency tables, as appropriate. As relative risks closely
approximated odds ratios (ORs), results are presented as
ORs. All P values are two-sided. Logistic regression was used
to model mortality probabilities in patients admitted in each
study period and to adjust for a priori-selected potential con-
founding factors. Simple logistic regression models that
included the main predictor of interest (study period as a sur-
rogate of IIT) were fitted initially. Period I was used as a refer-
ence prior to the implementation of insulin protocols. Adjusted
models included the main predictor of interest, the a priori-
specified confounders, significant predictors of mortality, and
additional confounders.
To explore the suggestion that different populations may
derive a variable degree of benefit from insulin therapy, sensi-
tivity analyses were conducted with varying assumptions
regarding the underlying study population, including subgroup
analyses for patients who were in the ICU for 3 days or less or
more than 3 days, and further restricting the analyses to surgi-
cal or medical populations and to patients who were admitted
after trauma.
Organ dysfunction scores, as measured by SOFA scores,
arise from a mixture of discrete and continuous processes,
making them ill-suited for standard statistical methods of anal-
ysis (for example, linear regression). We analyzed the SOFA
scores using a generalization of the limited dependent variable
model developed by Tobin [32] called the tobit model. The
tobit model simultaneously combines a probit regression for
the discrete component of the outcome (for example, zero
SOFA scores) and a normal error regression model for the
continuous component of the outcome (for example, SOFA
scores greater than zero). For a detailed exposition of the tobit
model and some of its extension, see Amemiya [33]. As SOFA
scores are highly skewed, we log-transformed SOFA scores
greater than zero to make the data more normal. We com-
puted robust standard error estimates of the tobit model's
regression coefficients using the non-parametric bootstrap of
Efron [34]. Hypothesis tests to investigate associations
between predictor variables and SOFA scores were per-
formed using Wald statistics. STATA statistical software (ver-
sion 9.2; StataCorp LP, College Station, TX, USA) was used
for all analyses. P values are two-sided.
Results
Study population and baseline characteristics
The study population consisted of 10,456 patients, of whom
2,366 were admitted during period I, 3,322 during period II,
and 4,768 during period III. The number of trauma patients in
the study cohort was 857 (36%) in period I, 1,203 (36%) in
period II, and 1,920 (40%) in period III. The distributions of
demographic and baseline characteristics of the patient pop-
ulation were broadly similar across the three periods (Table 1).
Compared with patients admitted during period I, history of
type I diabetes was less frequent in patients admitted in peri-
ods II and III, whereas type II diabetes was more common in
the latter periods (Table 1). Blood glucose at ICU admission
was lower in period III compared with the other two periods.
The average SAPS II and APS III scores were lower in period
III than in periods I and II. Requirement for mechanical ventila-
tion at ICU admission was less frequent over time.
Except for gender, ethnic group, history of diabetes I or II, and
weight, all variables in Table 1 were associated with hospital
mortality. In particular, the OR of hospital mortality for admis-
sion glucose was 1.0009 (95% confidence interval [CI]
1.0002, 1.0016; P = 0.014) for a 1 mg/dL increase in admis-
sion blood glucose.
Insulin use, glucose control, and hypoglycemia
The proportion of patients receiving insulin infusion increased
dramatically over the study periods, from 9% in period I to
25% in period II and then further to 43% in period III (Table 2).
Due to the lower threshold to initiate insulin treatment, and the
broadened exposure to insulin among patients without insulin
resistance, patients (on average) received lower doses of insu-
lin to control blood glucose in period III compared with the pre-
vious two periods. The average 6 a.m. blood glucose
concentrations as measured in the central laboratory
decreased from 144 mg/dL in period I to 139 mg/dL in period
I I  t o  1 2 9  m g / d L  i n  p e r i o d  I I I .  M o d e r a t e  ( < 6 5  m g / d L )  a n d
severe (<40 mg/dL) hypoglycemic events increased approxi-
mately threefold to fourfold from the first to the third study peri-
ods (Table 2). There was excess mortality associated with
hypoglycemia across the three time periods (Table 3). We
explored the association between mean glucose and mortality
restricting the analysis to period I (baseline). The OR of hospi-
tal mortality for mean blood glucose in period 1 was 1.0078
(95% CI 1.0043, 1.0112; P <0.01).Critical Care    Vol 12 No 1    Treggiari et al.
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Mortality
Overall, the crude hospital mortality rates were 14.1% in
period I, 15.7% in period II, and 14.4% in period III (Table 3).
These figures are within the range predicted by severity of ill-
ness scores (SAPS II and APS III). After adjusting for age at
admission, history of diabetes, SAPS II with age points
removed, admitting service, and mechanical ventilation at ICU
admission, the adjusted relative odds of hospital mortality
were not significantly different for patients who were admitted
during period II (OR 1.11, 95% CI 0.93, 1.31) or period III (OR
1.15, 95% CI 0.98, 1.32) compared with patients who were
admitted during period I (Table 4). In a model that included
admission blood glucose levels, the ORs of hospital mortality
Table 1
Baseline characteristics at intensive care unit admission stratified by study period
Clinical characteristic Period I
(n = 2,366)
1 Mar 01 to 28 Feb 02
Period II
(n = 3,322)
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)
1 Jul 03 to 28 Feb 05
Age in years, mean ± SD 51.1 ± 18.5 51.6 ± 19.1 51.6 ± 19.0
Male gender, n (%) 1,467 (62.0) 2,071 (62.4) 3,044 (63.9)
Race or ethnic group, n (%)a
Native American 70 (2.96) 62 (1.87) 105 (2.20)
Asian 142 (6.00) 220 (6.63) 294 (6.17)
African-American 224 (9.47) 291 (8.77) 369 (7.74)
Caucasian 1,651 (69.78) 2,310 (69.60) 3,422 (71.77)
Hispanic 91 (3.85) 156 (4.70) 228 (4.78)
Unknown 188 (7.95) 283 (8.52) 350 (7.34)
History of diabetes, n (%)
Type I 64 (2.7) 68 (2.1) 77 (1.6)
Type II 211 (8.92) 367 (11.1) 574 (12.0)
History of chronic disease, n (%)b 74 (3.2) 95 (2.9) 137 (2.9)
SAPS II, mean ± SDc 39.1 ± 18.1 39.3 ± 18.9 37.2 ± 18.4
APS III, mean ± SDd 53.1 ± 21.8 53.1 ± 23.3 50.5 ± 23.3
Trauma patients, n (%) 857 (36) 1,203 (36) 1,920 (40)
Injury Severity Score, mean ± SD 21.2 ± 10.9 20.8 ± 11.1 20.7 ± 10.6
Type of admission, n (%)
Surgical admission 1,440 (60.9) 2,003 (60.3) 3,084 (64.7)
Medical admission 926 (39.1) 1,319 (39.7) 1,684 (35.3)
Admitting service, n (%) n = 2,366 n = 3,314 n = 4,745
Surgical ICU 759 (32.1) 1,061 (32.0) 1,604 (33.8)
Medical ICU 756 (31.9) 1,025 (30.9) 1,303 (27.5)
Coronary ICU 170 (7.19) 270 (8.2) 350 (7.4)
Neurosurgical ICU 607 (25.7) 871 (26.3) 1,335 (28.1)
Burn ICU 74 (3.1) 87 (2.6) 153 (3.2)
Weight in kilograms, mean ± SD 83.0 ± 24.9 84.6 ± 26.0 84.5 ± 25.5
Admission glucose in mg/dL, mean ± SD 162.5 ± 88.9 161.3 ± 82.5 152.1 ± 69.1
Mechanical ventilation, n (%) 1,424 (60.2) 1,878 (56.5) 2,578 (54.1)
aRace or ethnic group was assigned on the basis of hospital record. bChronic disease defined according to Simplified Acute Physiology Score 
(SAPS) II criteria. cSAPS II can range from 0 to 162, with higher scores indicating a higher risk of death. dAPS is the acute physiology score of the 
APACHE (Acute Physiology and Chronic Health Evaluation) III score; it can range from 0 to 251, with higher scores indicating a higher risk of 
death. ICU, intensive care unit; SD, standard deviation.Available online http://ccforum.com/content/12/1/R29
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were 1.11 (95% CI 0.93, 1.31) in period II and 1.16 (95% CI
0.99, 1.37) in period III.
When the models were re-fitted to analyze mortality with cate-
gories of ICU length of stay (LOS), the ORs of hospital mortal-
ity were significantly higher in patients with an ICU LOS of 3
days or less (Table 4). In contrast, in patients with an ICU LOS
of greater than 3 days, there was no association between
study period and mortality (Table 4). Hospital mortality was not
decreased during period III in either the medical or surgical
population (whether trauma patients or others) (Table 5).
Overall, the crude ICU mortality rates were 9.0% in period I,
10.8% in period II, and 9.8% in period III. After adjustment, the
ORs of ICU mortality were significantly higher comparing
period III (OR 1.26, 95% CI 1.04, 1.53) with period I both in
the entire population (Table 4) and in the subgroups of
surgical and trauma patients (Table 5), but not in the medical
population.
Organ Dysfunction Score
Overall, the unadjusted mean SOFA score tended to decrease
over time across the study periods (Table 3). However, after
adjustment for imbalances in baseline characteristics, includ-
ing age, history of diabetes, SAPS II with age points removed,
admission blood glucose, and mechanical ventilation at ICU
admission, there was a 0.028 (95% CI -0.004, 0.06; P =
0.082) increase in the mean of the natural logarithm SOFA
score comparing patients in periods II and I and there was a
0.043 (95% CI 0.013, 0.073; P = 0.005) increase in the mean
of the log SOFA score comparing patients in periods III and I.
Discussion
The present study observed that implementation of IIT, with
the percentage of patients receiving insulin by infusion
increasing from 9% in period I to 42% in period III, was asso-
ciated with no hospital mortality benefit. Furthermore, an incre-
mental mortality increase associated with IIT was observed in
patients with an ICU stay of 3 days or less. These latter find-
ings are consistent with those from a similar subgroup in a ran-
domized controlled trial (RCT) of IIT in medical ICU patients
[24].
Our study has several potential limitations. Despite our effort
to control for confounding by assessing patient characteristics
across the three study periods and adjusting for any baseline
differences seen, the possibility of bias remains. However,
arguing in support of a true incremental mortality associated
with tighter glucose control was that the trend observed was
opposite of what might have been expected if confounding
had been present, given that several other clinical protocols
designed to improve patient outcomes were implemented in
Table 2
Insulin usage, glucose control, and safety of an intensive insulin protocol stratified by study period
Period I
(n = 2,366)
1 Mar 01 to 28 Feb 02
Period II
(n = 3,322)
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)
1 Jul 03 to 28 Feb 05
P valuea
Patients receiving insulin infusion, n (%) 206 (8.71) 817 (24.59) 2,027 (42.51) <0.01
Patients receiving subcutaneous insulin, n (%) 307 (14.21) 349 (13.93) 237 (8.65)c <0.01
Patients receiving any insulin, n (%) 513 (21.68) 1,166 (35.10)b 2,264 (47.48)c <0.01
Average daily dose of insulin, units/24 hours, mean ± SDd 72.4 (84.9) 55.7 (58.7) 47.5 (43.1) <0.01
Central lab 6 a.m. blood glucose n = 2,339 n = 3,278 n = 4,643
Mean ± SD 144.0 ± 38.1 138.7 ± 34.4 129.3 ± 30.3 <0.01
Median (IQR) 138 (120–160) 134 (117–153) 125 (112–140)
Average daily blood glucose, mean ± SD 146.6 ± 41.5 142.0 ± 37.4 132.6 ± 30.8 <0.01
Average daily blood glucose, median (IQR) 139 (121–161) 136 (120–156) 128 (115–143)
Average point-of-care blood glucose n = 700 n = 1,407 n = 2,610
Mean ± SD 167.4 ± 46.7 148.0 ± 36.8 131.6 ± 31.2 <0.01
Hypoglycemia <40 mg/dL, n (%)e 24 (1.01) 53 (1.60) 103 (2.15)c <0.01
Hypoglycemia <65 mg/dL, n (%)e 115 (4.86) 351 (10.57) 810 (16.99) <0.01
High-concentration glucose replacement, n (%)f 86 (3.63) 244 (7.34) 462 (9.69) <0.01
Hyperglycemia >200 mg/dL, n (%) 330 (14.1) 367 (11.1) 339 (7.26) <0.01
aAnalysis of variance or chi-square comparing the three study periods; period I is used as reference. bP <0.05 compared with period I (Wald test). 
cP <0.01 compared with period I (Wald test). dPatients receiving insulin infusion only. eNumber of patients with at least one episode of 
hypoglycemia; blood glucose values include both point-of-care and central laboratory measurements. fHigh-concentration glucose indicates 
administration of 50 mL of dextrose 50% (25 g). IQR, interquartile range; SD, standard deviation.Critical Care    Vol 12 No 1    Treggiari et al.
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the ICUs of the study hospital at around the same time as the
IIT protocols. Admittedly, two of these protocols would not be
expected to have any appreciable effect on mortality (invasive
diagnosis of ventilator-associated pneumonia and ventilator
weaning protocol) and the third (a protocol for lung protective
ventilation) was widely practiced prior to formal protocol
release. We did not observe any mortality differences between
the first and second halves of each study period, arguing
against an overall trend of increasing in mortality during the
study (data not shown). These arguments suggest that our
approach to evaluating the impact of the implementation of an
IIT protocol on mortality is a valid one.
The major strength of the current study lies in the large cohort
of patients included (>10,000) and the availability of extensive
clinical data that allowed adjustment for severity of illness
across time periods.
Four prior published studies have observed at least some
reduction in mortality associated with IIT in critically ill patients.
Van den Berghe and colleagues [23] reported the results of a
large randomized trial of IIT in patients admitted to a surgical
ICU, approximately 60% of whom had undergone cardiac sur-
gery. IIT (blood glucose range of 80 to 110 mg/dL) was asso-
ciated with a reduction in mortality from 8.0% to 4.6%
compared with conventionally treated patients (blood glucose
range of 180 to 200 mg/dL) in addition to reductions in multi-
ple morbidities [23]. In a subsequent study, van den Berghe
and colleagues [24] randomly assigned patients admitted to a
medical ICU to IIT or conventional blood glucose manage-
ment. There was no clear mortality benefit for IIT in the inten-
tion-to-treat population, whether for ICU (24.2% IIT group
versus 26.8% conventional treatment group) or hospital
(37.3% IIT versus 40% conventional treatment group) mortal-
ity. However, IIT was associated with reduced in-hospital mor-
tality in those patients who remained in the ICU for more than
3 days. In two studies that reported outcomes before and after
implementation of an intensive glucose management protocol,
mortality after implementation of the protocol was improved
compared with prior to protocol implementation [21,22]. How-
ever, neither study adjusted for severity of illness or other fac-
tors that may have changed over time.
There are several reasons that may explain why the results of
our study differ from these previous investigations of IIT. The
implementation of progressively more aggressive insulin ther-
apy protocols at our institution resulted in a large change in
practice: the use of IIT rose from 9.6% of patients in period I
to 42% in period III. Although this resulted in a reduction in
mean daily and mean morning glucose concentrations, with a
difference of approximately 15 mg/dL between periods I and
III, we were unable to consistently achieve blood glucose con-
centrations within the range of 80 to 110 mg/dL. It is possible
that the benefits of IIT are not achieved unless glucose con-
centrations are lower than 110 mg/dL.
Failure to achieve the targeted glucose levels reflects the diffi-
culty in application of clinical protocols to real-world practice,
outside the rigid confines of RCTs, and has been recognized
previously [35-37]. Despite an explicit protocol combined with
continuing educational efforts to alert physicians and nurses to
the potential benefits of tight glycemic control, glucose levels
Table 3
Crude estimates of mortality, length of stay, and organ dysfunction stratified by study period
Period I
(n = 2,366)
1 Mar 01 to 28 Feb 02
Period II
(n = 3,322)
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)
1 Jul 03 to 28 Feb 05
P valuea
ICU mortality, n (%) 214 (9.04) 358 (10.78) 465 (9.75) 0.086
OR (95% CI) of ICU mortality 1.00 1.21 (1.01, 1.46) 1.09 (0.92, 1.29)
Hospital mortality, n (%) 334 (14.12) 522 (15.71) 686 (14.39) 0.157
OR (95% CI) of hospital mortality 1.00 1.13 (0.97, 1.32) 1.02 (0.88, 1.17)
Patients in ICU <3 days n = 1,296 n = 1,829 n = 2,678
ICU mortality in patients in ICU <3 
days, n (%)
76 (5.86) 128 (7.0) 181 (6.76) 0.428
Hospital mortality in patients in ICU <3 
days, n (%)
122/1,174 (9.4) 203/1,829 (11.1) 283/2,678 (10.6) 0.310
Hospital mortality in patients with 
hypoglycemia <40 mg/dL, n (%)
9/24 (38) 23/53 (43) 41/103 (40) 0.863
Average SOFA score, mean ± SDb 1.65 (2.00) 1.77 (2.09) 1.62 (1.98) <0.01
Maximum SOFA score, mean ± SDb 2.82 (2.85) 2.96 (2.99) 2.74 (2.84) 0.004
aAnalysis of variance or chi-square comparing the three study periods; period I is used as reference. bScores for the Sequential Organ Failure 
Assessment (SOFA) can range from 0 to 24, with higher scores indicating a higher risk of death. CI, confidence interval; ICU, intensive care unit; 
OR, odds ratio; SD, standard deviation.Available online http://ccforum.com/content/12/1/R29
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(on average) remained approximately 20 mg/dL above the tar-
get range. This 'failure' likely occurred at several levels,
although we are unable to discern specific causes within the
limitations of our study design.
A major difference between our cohort and that included in the
trials of van den Berghe and colleagues [23,24] is the form of
nutritional support used. In the studies of van den Berghe and
colleagues, nutritional support was very aggressive: parenteral
nutrition was administered early in the course of care and com-
prised the vast majority of non-protein calories during the first
few days of ICU stay. This is in contrast to the practice at our
institution, where parenteral nutrition generally is not instituted
until 3 to 5 days after ICU admission. Parenteral nutrition
reduces endogenous glucose production and promotes
hyperglycemia in critical illness, effects which may be modu-
lated by insulin administration [38]. It is not clear how these
effects would translate into increased benefit from IIT.
Finally, our study differs from the trials of van den Berghe and
colleagues [23,24] in that we examined a mixed population of
critically ill patients, with approximately 60% of patients carry-
ing a surgical diagnosis at admission, with a high representa-
tion of trauma patients (approximately 56% of the entire study
cohort), including those with neurological injury. Our data sug-
gest that, if anything, ITT was associated with an increased
mortality among trauma patients, although the reasons for this
are not clear. Previous retrospective studies have found an
association between hyperglycemia and mortality in trauma
patients [1,2,39-43] and possibly a lower mortality temporally
associated with the implementation of an IIT protocol and
reduction in glucose variability [22,44]. However, our study is
the first to examine the effects of IIT on outcome in this popu-
lation, applying rigorous adjustments for patients' baseline
characteristics. Cardiac surgical services are not performed at
out institution; therefore, our surgical population differs from
that of the study of van den Berghe [23], in which the majority
of patients were recovering from cardiovascular surgery.
Several other studies also did not observe evidence of benefit
of ITT. A recently published multicenter RCT in 537 patients
with severe sepsis found no difference in mortality or organ
failure in IIT versus conventional glucose management groups
[45]. The incidence of severe hypoglycemia was increased in
patients randomly assigned to IIT (17.0% versus 4.1%).
Another recent study investigated the effect of intraoperative
IIT on the outcome of patients undergoing cardiac surgery
[46]. Patients were randomly assigned to IIT (glucose range of
80 to 100 mg/dL) or conventional treatment (glucose of less
than 200 mg/dL). The study reported higher mortality and
higher occurrence of strokes in the IIT group. A third recent
RCT found no mortality benefit and a much higher incidence
Table 4
Multivariable regression analysis (maximum likelihood estimation): intensive care unit and hospital mortalitya
Period II
(n = 3,322)b
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)b
1 Jul 03 to 28 Feb 05
OR (95% CI) P value OR (95% CI) P value
Entire ICU population
n = 3,310 n = 4,739
ICU mortality 1.20 (0.98, 1.47) 0.071 1.26 (1.04, 1.53) 0.019
Hospital mortality 1.11 (0.93, 1.31) 0.248 1.15 (0.98, 1.35) 0.088
Entire ICU population, ICU LOS ≤ 3 days
n = 1,808 n = 2,619
ICU mortality 1.21 (0.84, 1.74) 0.317 1.65 (1.16, 2.33) 0.005
Hospital mortality 1.17 (0.87, 1.57) 0.288 1.47 (1.11, 1.93) 0.007
Entire ICU population, ICU LOS >3 days
n = 1,484 n = 2,033
ICU mortality 1.21 (0.95, 1.54) 0.125 1.14 (0.90, 1.44) 0.268
Hospital mortality 1.08 (0.87, 1.33) 0.501 1.01 (0.83, 1.24) 0.918
aAll estimates are adjusted for admission age, history of diabetes, Simplified Acute Physiology Score (SAPS) II with age points removed, 
mechanical ventilation at ICU admission, and admitting service. bPeriod I is used as reference category for all analyses (n = 2,366 for the entire 
ICU population, n = 1,282 for patients in ICU ≤3 days, and n = 1,067 for patients in ICU >3 days). CI, confidence interval; ICU, intensive care 
unit; LOS, length of stay; OR, odds ratio.Critical Care    Vol 12 No 1    Treggiari et al.
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of hypoglycemia in a group of patients treated to maintain glu-
cose less than 108 mg/dL for 48 hours after cardiac arrest
compared with a group treated to maintain glucose less than
144 mg/dL [26]. A prospective consecutive series of 818
patients admitted to a trauma ICU found no reduction in mor-
tality or infectious complications in association with the imple-
mentation of a normoglycemic management protocol (glucose
goal of 80 to 110 mg/dL) [47]. Additionally, preliminary results
from another recently completed randomized trial of IIT in ICU
patients showed no significant mortality difference and an
increase in the risk of hypoglycemia [27,48].
The reason that IIT may result in increased mortality is unclear
but may be related to a direct effect of insulin or to insulin-
induced hypoglycemia. Two previous studies have found an
association between ICU mortality and insulin administration
[49,50]; the mechanism by which insulin may confer harm is
not clear but might be related to anabolic effects, similar to
growth hormone [51-53]. Two studies have examined the
association between hypoglycemia and mortality in critically ill
patients using case control methodology, with one finding no
effect [54] and the other suggesting an independent associa-
tion between severe hypoglycemia and mortality [55]. Further
exploration of these areas is warranted.
It is unclear why we found increases in ICU mortality in the
entire cohort and in some subgroups whereas there were only
trends toward increased hospital mortality (Tables 4 and 5).
For hospital mortality, the signal in the data could be attenu-
ated due to the underlying noise of hospital deaths not related
to glycemic control. It is also possible that ICU mortality
reflects more glycemic control-related deaths than deaths
from all causes. The association between period and ICU or
hospital mortality was stronger in patients with a short ICU
stay. This finding was also observed in the second randomized
trial of van den Berghe and colleagues [24]. It is also possible,
though speculative, that IIT confers some longer-term survival
benefit that offsets adverse effects seen during the ICU stay.
Conclusion
We observed that IIT in a mixed cohort of critically ill patients
was not associated with a reduction in hospital mortality, and
was associated with increased ICU and hospital mortality in
some subgroups. These results, combined with data from the
most recently concluded randomized trials, suggest that broad
implementation of IIT may be premature and that additional
randomized trials in diverse groups of critically ill patients are
necessary.
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Table 5
Multivariable regression analysis: intensive care unit and hospital mortality in population subgroupsa
Period I
(n = 2,366)
1 Mar 01 to 28 Feb 02
Period II
(n = 3,322)
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)
1 Jul 03 to 28 Feb 05
OR (95% CI) OR (95% CI) OR (95% CI)
Surgical and trauma ICU population
n = 1,429 n = 1,991 n = 3,011
ICU mortality 1.00 1.27 (0.97, 1.67) 1.40 (1.08, 1.82)b
Hospital mortality 1.00 1.18 (0.94, 1.48) 1.18 (0.95, 1.47)
Trauma ICU populationc
n = 854 n = 1,195 n = 1,866
ICU mortality 1.00 1.25 (0.85, 1.84) 1.76 (1.23, 2.53)d
Hospital mortality 1.00 1.12 (0.81, 1.54) 1.16 (0.85, 1.57)
Medical ICU population
n = 920 n = 1,301 n = 1,641
ICU mortality 1.00 1.12 (0.83, 1.52) 1.10 (0.82, 1.47)
Hospital mortality 1.00 1.02 (0.87, 1.41) 1.11 (0.87, 1.41)
aAll estimates are adjusted for admission age, history of diabetes, Simplified Acute Physiology Score (SAPS) II with age points removed, and 
mechanical ventilation at ICU admission. bP <0.05 multivariable regression (maximum likelihood estimation). cIn the trauma ICU population, the 
models also adjust for Injury Severity Score. dP <0.01 multivariable regression (maximum likelihood estimation). CI, confidence interval; ICU, 
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Appendix 1
Intensive insulin protocol used during period II of the study.
These orders were modified slightly for use during period III in
order to achieve a glucose goal closer to 81 to 110 mg/dL.
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